Track topics on Twitter Track topics that are important to you
Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody derived binding fragment fused to signaling domains. The antibody derived binding fragment allows for the recognition of cancer associated targets and the signaling domains are T cell signaling domains that are components required for T cell activation. When CARs are expressed on a T cell, they allow the T cell to specifically identify and eliminate malignant cancer cells. This is a promising new therapeutic approach known as adoptive cell therapy.
FLT3 (a.k.a., Fms-Related Tyrosine Kinase 3) is a tumor-associated antigen that is known to be expressed on the cell surface of a majority of infant acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). This technology concerns the development of CARs comprising an antigen-binding fragment derived from a FLT3 targeting antibody. The resulting CARs can be used in adoptive cell therapy treatment for ALL or AML and other tumors which express FLT3.
Discovery (Lead Identification)
Licensing and research collaboration
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...